White Blood Cell Count and Your Genetics

By the ExomeDNA Science Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

White blood cell count — measured in every standard complete blood count (CBC) — reflects your circulating pool of immune cells, with a normal reference range of approximately 4,000 to 11,000 cells per microliter of blood. Genome-wide association studies across more than 80,000 individuals in diverse populations have identified multiple genetic loci that influence where within that normal range a person's baseline WBC count tends to fall. Below: what those genes do, what the research found, and how to use your result.

What is white blood cell count?

White blood cells, collectively called leukocytes, are the cellular arm of the immune system. The CBC measures their total count along with a differential — the proportional breakdown of the five major subtypes:

Neutrophils (50–70% of total WBC): the first-responder cells that engulf and destroy bacteria and fungi.
Lymphocytes (20–40%): including T cells, B cells, and natural killer cells, which coordinate adaptive immune responses and immunological memory.
Monocytes (2–8%): large phagocytic cells that circulate in blood and migrate into tissues to become macrophages.
Eosinophils (1–4%): involved in responses to parasites and in allergic inflammation.
Basophils (<1%): rare cells that release histamine and other mediators during allergic reactions.

The total WBC count captured in ExomeDNA's report reflects genetic influences on the aggregate pool. Clinically, WBC is one of the most ordered laboratory tests worldwide because it provides a rapid window into immune status: transient elevations accompany infections; persistent elevations may warrant further evaluation; counts below roughly 4,000 cells per microliter (leukopenia) can signal vulnerability to infection.

Critically, within the normal range, there is no universally "better" or "worse" number. Someone whose genetics place them toward the lower end of normal is not immunodeficient. Someone at the higher end does not have a disease. Your genetic set-point tells you where your baseline tends to sit — context that becomes genuinely useful when interpreting future lab results.

The genetics behind white blood cell count

Large-scale GWAS has identified dozens of variants influencing total WBC and its subtypes. The ExomeDNA report draws on a curated set of well-replicated loci across several authorized genes, including AAK1, ABCA2, ABCA7, ABCC5, ABL1, and ABO.

ABL1 (Abelson murine leukemia viral oncogene homolog 1) is the most clinically recognizable gene in this list — though the reason it is famous is quite different from its role here. ABL1 encodes a non-receptor tyrosine kinase that, in its normal form, is essential for regulating hematopoietic cell proliferation, differentiation, and survival. Normal ABL1 is activated by growth factor receptors and governs how many leukocytes are produced from bone marrow progenitors. Common variants in ABL1 influence the set-point of this production, contributing to population-level variation in leukocyte counts without any disease-associated mechanism. It is worth noting that ABL1 is also the gene rearranged by the Philadelphia chromosome translocation, which creates the BCR-ABL fusion kinase that drives chronic myeloid leukemia (CML) — the target of imatinib (Gleevec). This translocation is a somatic mutation acquired in blood stem cells, entirely distinct from the inherited germline variants that ExomeDNA analyzes. The two facts simply share a gene address; they have no clinical relationship.

ABCA7 (ATP-binding cassette transporter A7) is expressed at high levels in monocytes, macrophages, and brain microglia. Its primary biochemical role is mediating cholesterol efflux and facilitating phagocytosis of apoptotic cells — the clean-up process by which immune cells remove cellular debris. Variants in ABCA7 that influence WBC count appear to do so through effects on monocyte count and function. Interestingly, ABCA7 is also one of the more reliably replicated genetic associations with Alzheimer's disease risk: the connection makes biological sense because peripheral monocytes and brain microglia share developmental origin, signaling machinery, and phagocytic function. The gene's role in WBC variation is thus a peripheral readout of the same immune-lipid biology that influences neuroinflammation.

ABCA2 (ABC transporter A2) is highly expressed in oligodendrocytes and myeloid immune cells. It regulates cholesterol and sphingolipid transport, affecting the lipid composition of immune cell membranes, which in turn influences cell signaling and proliferative capacity. ABCC5 (MRP5) exports cyclic nucleotides — cGMP and cAMP — from hematopoietic cells; because cyclic nucleotide levels regulate immune cell signaling cascades and proliferation rates, variants in ABCC5 can shift the equilibrium of leukocyte production.

AAK1 (AP-2-associated protein kinase 1) contributes a distinct mechanistic angle: it regulates clathrin-mediated endocytosis by phosphorylating the AP-2 adaptor complex. In immune cells, receptor internalization after cytokine or growth factor binding is the primary mechanism for terminating proliferative signals. AAK1 variants that alter receptor recycling efficiency in leukocytes can therefore alter how quickly a proliferative signal is switched off — influencing the steady-state leukocyte number.

ABO blood group rounds out the authorized gene list. ABO influences von Willebrand factor levels and glycosylation patterns in inflammatory signaling molecules, contributing modest but replicated effects on total WBC count across cohorts.

What the research says

Research base: Robust.

The genetics of white blood cell count is among the most extensively studied domains in hematological GWAS. The evidence base spans more than a decade of large-scale replication across ethnically diverse cohorts.

The foundational signal emerged from a 2010 genome-wide study of hematological and biochemical traits in a Japanese biobank cohort (Kamatani et al., PMID 20139978), which identified multiple loci influencing WBC and its subtypes. A critical replication milestone came in 2011 when Reiner et al. (PMID 21738479) extended GWAS to 16,388 African Americans — a cohort that substantially broadened the cross-ancestry evidence base — and Nalls et al. (PMID 21738480) simultaneously reported multiple loci associated with WBC phenotypes across tens of thousands of participants.

Key statistics from the research base:

The 2014 trans-ethnic meta-analysis by Keller et al. (PMID 25096241) synthesized findings across African American, European, and Hispanic cohorts, confirming that the major WBC loci are not population-specific — they are shared across ancestries with effect sizes that replicate transatlantically.
The 2016 Astle et al. paper (PMID 27863252) analyzed the allelic landscape of blood cell traits across approximately 170,000 UK Biobank participants, identifying over 130 independent signals across blood cell phenotypes, including WBC subtypes. This remains one of the largest single hematological GWAS ever conducted.
Kanai et al. (PMID 29403010) linked WBC-associated loci in a Japanese population to cellular phenotypes, confirming that the genetic architecture is partly population-specific in fine-mapping detail even when the broad loci replicate.

Numbered findings from replication:

WBC GWAS hits replicate across European, African American, Hispanic/Latino, and East Asian cohorts — cross-ancestry validation is among the strongest for any hematological trait.
The genes influencing total WBC overlap substantially with genes influencing individual subtypes (neutrophils, lymphocytes, monocytes), suggesting shared regulatory architecture rather than trait-specific pathways.
Rare coding variants in genes such as CXCR2 (identified by Auer et al., PMID 24777453) contribute to WBC variation at lower frequencies, meaning the genetic architecture spans both common and rare variants.
Whole-genome sequencing in isolated populations (Southam et al., PMID 28548082) uncovered additional loci not visible in standard array-based GWAS, indicating the architecture is still being mapped.
The population-level GWAS signal for WBC overlaps with genetic architecture implicated in autoimmune disease susceptibility, consistent with shared inflammatory pathways.

How white blood cell count affects you

White blood cell count is a biomarker, not a clinical finding. Understanding your genetic set-point is useful in four practical contexts:

Interpreting future labs. If your genetics suggest a constitutional tendency toward the lower end of the normal WBC range (for example, around 4,500–6,000 cells/μL), a lab result of 4,800 is unremarkable for you — even though an uninformed clinician might flag it as "low-normal." Conversely, if your genetic baseline sits higher, a value of 10,500 during a respiratory illness may represent a proportionally smaller elevation than it would for someone with a lower set-point. Context matters, and knowing your genetic baseline provides one anchor for interpretation.

Distinguishing transient from chronic shifts. A WBC increase during an active infection is expected and healthy — it reflects appropriate immune mobilization. WBC counts typically normalize within one to two weeks after infection resolution. Persistently elevated WBC in the absence of acute illness — especially counts repeatedly above 11,000 cells/μL — warrants clinician evaluation to rule out inflammatory conditions, medications, or other causes. Your genetic result characterizes your baseline, not your response to acute illness.

Lifestyle factors that measurably influence WBC. Several modifiable behaviors have documented associations with chronic WBC elevation through low-grade inflammation:

Smoking is among the strongest behavioral drivers of chronically elevated WBC. Smokers consistently show WBC counts 1,000–2,000 cells/μL higher than non-smokers, reflecting ongoing airway and systemic inflammation. Cessation gradually reduces this elevation over months to years.
Excess adiposity is independently associated with higher baseline WBC via adipose-tissue-derived inflammatory cytokines (adipokines). The association is graded across BMI ranges.
Chronic psychological stress activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, both of which mobilize leukocytes from marginated pools and bone marrow.
Disrupted sleep (chronic short sleep duration or poor sleep quality) is associated with higher circulating inflammatory markers, including WBC elevation.
Heavy alcohol use dysregulates immune cell production and is associated with both leukopenia in severe cases and elevated inflammatory WBC counts in chronic moderate-heavy consumption patterns.

The ABO connection. Your ABO blood type — determined by the same ABO gene that contributes to WBC count variation — also influences your von Willebrand factor levels and inflammatory cytokine glycosylation patterns. This is one illustration of how genetic architecture in the immune and coagulation systems overlaps.

Working with your white blood cell count result

Because WBC is a biomarker rather than a disease outcome, actionable steps center on using the genetic context intelligently and maintaining the lifestyle conditions that keep baseline inflammatory tone in check.

Share the result with your primary care clinician before your next CBC. Your genetic WBC set-point is most useful as context for a clinician who orders your complete blood count. A phrase like "my direct-to-consumer genomic report suggests I tend toward the lower (or higher) end of the normal WBC range" gives a clinician a useful prior — particularly when comparing your results across years.
Establish a personal baseline with serial CBCs. One result is a snapshot; two or three results over time, taken when you are healthy, define your individual normal. Request CBC at your annual physical and retain copies. The trend matters more than any single value.
Prioritize smoking cessation if applicable. The WBC-elevating effect of tobacco smoke is among the most reproducible lifestyle-WBC associations in the literature, and it represents chronic inflammatory strain on the immune system — not merely a benign count elevation.
Adopt anti-inflammatory dietary patterns. The Mediterranean dietary pattern (high in olive oil, vegetables, legumes, fish, and whole grains) is associated with reduced circulating inflammatory markers including lower baseline WBC in prospective cohort studies. This is not a WBC-specific intervention — it represents broadly beneficial inflammatory modulation.
Address chronic stressors and sleep quality. Both chronic psychological stress and insufficient sleep activate inflammatory pathways measurably. Standard sleep hygiene practices and stress-reduction approaches (aerobic exercise, mindfulness-based interventions) have published data on inflammatory marker reduction.
Limit heavy alcohol consumption. Chronic heavy alcohol use dysregulates hematopoietic cell production. Moderate-to-none consumption is associated with lower inflammatory WBC burden compared to heavy use patterns.

Sibling traits in the Immune and Blood Health category:

Neutrophil Count — the largest WBC subtype, sharing many of the same GWAS loci; your neutrophil-specific result refines the total WBC picture.
Lymphocyte Count — driven by partially distinct genetic architecture, reflecting adaptive vs. innate immune compartment variation.
Monocyte Count — particularly relevant given ABCA7's monocyte-specific biology; monocyte count shares genetic signal with both WBC total and Alzheimer's risk pathways.

Cross-category related traits:

Inflammatory Markers (C-Reactive Protein) — CRP is the classical systemic inflammation biomarker; genetic WBC set-point and genetic CRP levels are partially correlated through shared inflammatory loci.
Alzheimer's Disease Risk — the ABCA7 gene that contributes to WBC variation is one of the stronger common-variant Alzheimer's signals; understanding this shared biology illuminates why immune function and neurodegeneration are linked.
ABL1 Gene — hematopoietic tyrosine kinase; WBC set-point regulation through myeloid progenitor proliferation.

Frequently asked questions

1. Does a higher genetic WBC set-point mean I am more immune-protected?

Not in a straightforward way. A higher baseline WBC within the normal range reflects that your genetics tend to produce or maintain more circulating leukocytes at rest. This does not translate directly to better pathogen clearance — immune effectiveness depends on cell quality, receptor function, and coordination between subtypes, not just total count. Conversely, a lower genetic set-point does not indicate immunodeficiency; it is a normal variant.

2. Can my diet or lifestyle actually change my WBC count?

Yes, within limits. Behavioral factors — smoking, sleep, stress, alcohol, diet — can chronically elevate or modulate WBC through their effects on systemic inflammatory tone. These shifts occur on top of your genetic baseline. The genetic component establishes the set-point; lifestyle factors shift the operating point around it.

3. My doctor mentioned leukocytosis. Is that related to my ExomeDNA result?

Leukocytosis (WBC above roughly 11,000 cells/μL) has many causes: infection, inflammation, medications (corticosteroids, lithium), physiological stress, and rarely hematological conditions. Your ExomeDNA result characterizes your constitutional genetic baseline — it does not predict or explain acute leukocytosis, which requires clinical evaluation of the cause in context.

4. Why does the ABL1 gene appear in a wellness DNA report if it is the leukemia gene?

ABL1 is a large gene with many functions. The BCR-ABL fusion oncogene created by the Philadelphia chromosome translocation is a somatic (acquired) rearrangement in blood stem cells during a person's lifetime — it is not inherited. ExomeDNA analyzes inherited germline variants in ABL1 that influence normal hematopoietic progenitor cell activity and WBC count set-point. These are entirely different biological events that happen to share a gene locus.

5. How many people were studied to establish these genetic associations?

The white blood cell count GWAS literature is among the most robustly powered in hematological genetics. The 2016 UK Biobank analysis by Astle et al. alone included approximately 170,000 participants. Combined, the studies cited in ExomeDNA's WBC trait span well over 200,000 individuals across African American, European, Hispanic/Latino, and East Asian cohorts.

6. Should I get a complete blood count done after reading this result?

That decision belongs with a clinician, but generally: if you are due for routine bloodwork, this result provides useful context to share with your doctor. With no acute symptoms and a recent CBC within normal range, there is no urgency. The genetic result is informational context, not a trigger for additional testing.

References:

Kamatani Y et al. (2010). Genome-wide association study of hematological and biochemical traits in a Japanese population. Nature Genetics. PMID 20139978.
Reiner AP et al. (2011). Genome-wide association study of white blood cell count in 16,388 African Americans. PLOS Genetics. PMID 21738479.
Keller MF et al. (2014). Trans-ethnic meta-analysis of white blood cell phenotypes. Human Molecular Genetics. PMID 25096241.
Astle WJ et al. (2016). The allelic landscape of human blood cell trait variation and links to common complex disease. Cell. PMID 27863252.
Kanai M et al. (2018). Genetic analysis of quantitative traits in the Japanese population links cellular levels to complex disease. Nature Genetics. PMID 29403010.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.

Browse all traits →